Mayur M. Amonkar
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Melanoma and MAPK Pathways, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research
Most-Cited Works
- → Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis(2005)392 cited
- → Obesity and health-related quality of life: a cross-sectional analysis of the US population(2003)315 cited
- → Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population(2003)266 cited
- → Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial(2015)257 cited
- → Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial(2021)213 cited
- → Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review